Treatment Resistant Depression Clinical Trial
— rTMSOfficial title:
Study of Individualized Accurate Targeting rTMS Intervention on Motivational Anhedonia of Treatment Resistant Depression and Brain Network Mechanism
NCT number | NCT03991572 |
Other study ID # | FYu |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2018 |
Est. completion date | December 31, 2021 |
Study of individualized accurate targeting rTMS intervention on motivational anhedonia of treatment resistant depression and brain network mechanism
Status | Recruiting |
Enrollment | 90 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 55 Years |
Eligibility |
1. Meet criteria of depression assessed by at least two psychiatrists according to the
five version of Diagnostic and Statistical Manual of Mental Disorders. 2. The score of Hamilton Depression Rating Scale-24 was larger than 18. 3. The score of Montgomery-Asberg Depression Rating Scale was larger than 15. 4. Psychotropic medication was at steady dosages for at least 4 weeks prior to study entry and for the duration of the trial. 5. Age was between 18 to 60 year old. 6. The intelligence quotient score was larger than 85. 7. The education duration was at least 6 years. 8. The vision or corrected vision was normal. 9. Right handedness. 10. No treatment of rTMS, transcranial direct current stimulation or electroconvulsive therapy before. Exclusion Criteria: 1. History of significant head trauma or neurological disorders. 2. Alcohol or drug abuse. 3. Focal brain lesions. 4. History of seizure. 5. First degree relative with epilepsy, significant neurological illness or head trauma, endocrine disease. 6. Significant unstable medical condition. 7. Recent aggression or other forms of behavioral dyscontrol. 8. Left-handedness. 9. Pregnancy. 10. Current alcohol or drug abuse 11. Inability to provide informed consent. 12. Patients with contraindications or factors affecting imaging quality, such as pacemakers, cochlear implants, or hearts Cerebrovascular metal stent, and metal denture. |
Country | Name | City | State |
---|---|---|---|
China | Anhui Medical University | Hefei | Anhui |
Lead Sponsor | Collaborator |
---|---|
Anhui Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in Hamilton Depression Scale | The participants' depression symptom assessed by the Hamilton Depression Scale and the Beck Depression Self-Rating Scale change from baseline after the treatment. | baseline;15 day post-treatment | |
Primary | Change from baseline in Motivation and Pleasure Scale | The severity of participants' anhedonia assessed by the Motivation and Pleasure Scale change from baseline after the treatment. | baseline;15 day post-treatment | |
Secondary | The change from baseline in behavioral results of Monetary Incentive Delay task | The motivational anhedonia assessed by accuracy and response time in Monetary Incentive Delay task | baseline; 15 day post-treatment change from baseline after the treatment. | |
Secondary | The change from baseline in event-related brain potentials during the monetary incentive delay task | The amplitudes of brain potentials of contingent negative variation, P3 and Feed-back negativity assessed by event-related brain potentials methods change from baseline after the treatment. | baseline; 15 day post-treatment | |
Secondary | The change from baseline in neuroimaging results of functional magnetic resonance imaging scan in multimodalities | The activation of nucleus accumbens, dorsal lateral prefrontal cortex and the functional connection these brain area assessed by functional magnetic resonance imaging scan in multimodalities change from baseline after the treatment. | baseline; 15 day post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04124341 -
PCS in Severe Treatment Resistant Depression
|
N/A | |
Recruiting |
NCT03887715 -
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
|
N/A | |
Completed |
NCT04727229 -
Stellate Ganglion Block for Major Depressive Disorder.
|
Phase 4 | |
Completed |
NCT04634669 -
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
|
Phase 2 | |
Withdrawn |
NCT03175887 -
Investigational TMS Treatment for Depression
|
N/A | |
Completed |
NCT03134066 -
Neurocognitive Features of Patients With Treatment-Resistant Depression
|
||
Active, not recruiting |
NCT01984710 -
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
|
N/A | |
Completed |
NCT01935115 -
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
|
Phase 4 | |
Terminated |
NCT01687478 -
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
|
Phase 3 | |
Completed |
NCT00531726 -
Berlin Deep Brain Stimulation Depression Study
|
N/A | |
Recruiting |
NCT04041479 -
Biomarker-guided rTMS for Treatment Resistant Depression
|
Phase 3 | |
Recruiting |
NCT05870540 -
BPL-003 Efficacy and Safety in Treatment Resistant Depression
|
Phase 2 | |
Recruiting |
NCT04959253 -
Psilocybin in Depression Resistant to Standard Treatments
|
Phase 2 | |
Completed |
NCT04856124 -
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
|
||
Recruiting |
NCT03272698 -
ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression
|
Phase 4 | |
Active, not recruiting |
NCT04451135 -
CET- REM (Correlating ECT Response to EEG Markers)
|
N/A | |
Recruiting |
NCT05680220 -
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
|
N/A | |
Completed |
NCT03288675 -
Stepped Care aiTBS 2 Depression Study (Ghent)
|
N/A | |
Recruiting |
NCT06138691 -
KET-RO Plus RO DBT for Treatment Resistant Depression
|
Phase 1 | |
Terminated |
NCT02675556 -
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
|
Phase 1 |